You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
STOCKHOLM-- Alzheimer's researchers gathered here last month with a sense of urgency and optimism about possible treatments--and perhaps preventions--for the mind-robbing disease. The 4000 attendees heard about progress on several fronts, including possible vaccines and treatments aimed at either blocking formation of b amyloid, a small peptide thought to trigger the loss of brain neurons, or at dissolving the abnormal b-amyloid deposits that are a hallmark of the disease. This special focus also explores a debate over which drugs to test in a prevention trial.
